|1.||Schally, Andrew V: 33 articles (05/2014 - 03/2002)|
|2.||Reubi, Jean Claude: 17 articles (01/2015 - 04/2002)|
|3.||Halmos, Gabor: 16 articles (10/2012 - 10/2003)|
|4.||Schally, A V: 14 articles (05/2008 - 03/2000)|
|5.||Waser, Beatrice: 13 articles (08/2015 - 07/2002)|
|6.||Chen, Xiaoyuan: 13 articles (10/2013 - 08/2004)|
|7.||Maecke, Helmut R: 12 articles (08/2015 - 09/2004)|
|8.||Smith, Charles J: 11 articles (02/2015 - 03/2005)|
|9.||Hoffman, Timothy J: 11 articles (02/2015 - 05/2003)|
|10.||Nagy, Attila: 10 articles (01/2006 - 04/2003)|
12/15/1997 - "The biodistribution study showed that the tumor localization (14.9 +/- 8.2% injected dose/gram; ID/g) of [125I]-mIP-bombesin 2 days after administration of AdCMVGRPr was significantly greater than its localization in other organs (P < 0.003) and was significantly greater than in AcCMVLacZ- and saline-treated mice (P < 0.003). "
08/01/1997 - "Additionally, tumors transduced in vivo to express GRPr demonstrated significantly greater localization of [125I]-mIP-bombesin when compared with [125I]-Tyr4-bombesin."
06/01/2008 - "In these analogues is replaced one ([D-Phe12]BN, [Tyr4]BN, and [Lys3]BN) or two ([Tyr4,D-Phe12]BN, [D-Phe12,Leu14]BN, and [Leu13-(R)-Leu14]BN) amino acid residues within the peptide chain with a synthetic amino acid, creating antagonists to bombesin, which are useful in the treatment of cancer. "
01/01/2011 - "In contrast, conjugation to a bombesin analog lacking the receptor-binding domain failed to increase the cytotoxicity of MG2, suggesting that bombesin conjugation enhances the cytotoxicity of MG2 in cancer cells through improved binding. "
04/05/2010 - "Bombesin and its analogues show promise for the targeted delivery of radioactive and chemotherapeutic agents to a wide variety of solid tumors. "
|2.||Prostatic Neoplasms (Prostate Cancer)
05/06/2013 - "Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer."
07/01/2010 - "A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues."
03/01/2015 - "The aim of this first-in-man study was to demonstrate the feasibility, safety, and tolerability, as well as provide dosimetric data and evaluate the imaging properties, of the bombesin analogue BAY 864367 for PET/CT in a small group of patients with primary and recurrent prostate cancer (PCa). "
01/01/2012 - "Scintigraphy is generally not the first choice treatment for prostate cancer, although successful studies using bombesin analog radiopeptides have been performed. "
02/01/2011 - "In the present study, we developed an (18)F-labeled bombesin analog, (18)F-BAY 86-4367, which is currently being clinically tested for use in PET of prostate cancer. "
02/01/2014 - "There was a significant GRP receptor density gradient (P ≤ 0.005), increasing from normal prostate glands (mean relative optical density, ROD, of ¹²⁵I-Tyr⁴ -bombesin binding: 0.17) over atypical glands without increased MIB-1 labeling (0.28) and atypical glands with increased MIB-1 expression (0.44) to high grade PIN and adenocarcinoma (0.64 and 0.58, respectively). "
07/01/2006 - "We hypothesized that pancreatic ductal adenocarcinoma (PDAC) might be imaged with the inverse strategy, that is by the design of a nanoparticle-conjugate targeted to bombesin (BN) receptors present on normal acinar cells of the pancreas. "
04/01/2006 - "Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma."
11/15/1996 - "Bombesin may be involved as a growth factor in the development of pancreatic ductal adenocarcinoma in humans. "
09/01/1994 - "Bombesin inhibits growth of pancreatic ductal adenocarcinoma (H2T) in nude mice."
|4.||Neoplasm Metastasis (Metastasis)
01/01/2002 - "In eight of the nine cases with pathological lymph node metastases, expression of MMP-9 and bombesin was also noted in metastatic sites. "
01/01/1985 - "Very high concentrations of bombesin were identified in these metastases."
03/01/2003 - "Multi-receptor tumour targeting using the combination of bombesin and NPY(Y(1)) analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases."
11/01/2001 - "Increased bombesin expression was correlated with colorectal adenocarcinomas exhibiting poor histological grade and their liver metastases. "
01/01/2001 - "Bombesin significantly increased the incidence of peritoneal metastasis from gastric cancers through the activation of Rho protein."
|5.||Duodenal Ulcer (Curling's Ulcer)
11/01/1985 - "Bombesin and G-17 dose responses in duodenal ulcer and controls."
03/01/1983 - "An increased parietal cell mass could explain the higher gastric acid response after bombesin infusion in our group of patients with duodenal ulcer."
01/01/1979 - "Bombesin was found to be a very potent stimulator of gastric acid secretion in patients with duodenal ulcer. "
11/01/1985 - "Serum gastrin with bombesin stimulation was significantly greater in duodenal ulcer (maximum 467 pg/ml) than in controls (153 pg/ml), while in seven of the DU group tested gastrin levels after a meal were not different from that seen in five of the normal controls. "
03/01/1993 - "The total net increase of somatostatin in the presence of bombesin was significantly less in duodenal ulcer patients (0.10 +/- 0.02 ng/mg wet w.) than in normal subjects (1.45 +/- 0.24 ng/mg wet w.) (p < 0.01). "
|1.||Bombesin Receptors (Bombesin Receptor)
|2.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|6.||Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)
|7.||Adrenocorticotropic Hormone (ACTH)
|9.||Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
|10.||Gonadotropin-Releasing Hormone (GnRH)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)
|5.||Total Parenteral Nutrition